Allergen Modification for Safer Immunotherapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immunotherapy methods for allergies, such as those caused by food or insect venoms, are time-consuming, often ineffective, and carry a risk of severe allergic reactions due to insufficient modification of allergens, which does not adequately reduce allergenicity while maintaining immunogenicity.
Innovation Solution
A process involving reduction and alkylation followed by treatment with a cross-linking agent like glutaraldehyde to modify allergens, reducing IgE-binding while preserving T-cell activation, thereby enhancing the safety and efficacy of immunotherapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If allergens are modified to reduce allergenicity, then safety is improved, but immunogenicity may be reduced
Solution Approach 1:
The patent applies selective modification to specific regions of the allergen protein. By targeting only certain amino acid residues (such as lysine residues in IgE-binding epitopes) for modification while leaving other regions intact, the method reduces allergenicity locally without compromising the overall immunogenicity of the protein. This localized approach allows T-cell epitopes to remain functional while IgE-binding sites are modified.
Solution Approach 2:
The patent employs controlled chemical modification parameters to achieve the desired balance. By adjusting parameters such as the degree of modification, pH, temperature, and reaction time during the modification process, the method optimizes the reduction of allergenicity while preserving immunogenicity. The modification level is carefully controlled to avoid excessive alteration that would compromise T-cell recognition.
2Reliability
If traditional immunotherapy is used, then desensitization is attempted, but treatment duration is excessive and safety is compromised
Solution Approach 1:
The patent applies preliminary modification to allergens before immunotherapy administration. By pre-modifying the allergens to reduce their allergenicity while preserving immunogenicity, the method prepares the therapeutic agent in advance to elicit protective immune responses more effectively and safely. This preliminary action reduces the risk of adverse reactions during treatment and accelerates the desensitization process.
3Object-affected harmful factors
If allergens are heavily modified to eliminate allergic reactions, then safety is improved, but therapeutic effectiveness is reduced
Solution Approach 1:
The patent applies partial modification to allergens, modifying only sufficient portions to reduce allergenicity while maintaining adequate immunogenicity. By applying modification to a controlled extent rather than completely, the method achieves the minimum necessary reduction in allergic reactivity while preserving the therapeutic capacity to induce protective immunity. This partial action approach avoids over-modification that would eliminate therapeutic effectiveness.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modified allergens significantly reduce allergic reactions, allowing for safer and more effective desensitization, enabling the treatment of previously unsuitable allergies and shortening the duration of immunotherapy.
Implementation Method 1
The modification comprises the steps of reduction and treatment with a cross-linking agent
Implementation Method 2
treatment with a cross-linking agent like glutaraldehyde to modify allergens, reducing IgE-binding while preserving T-cell activation
Data Source
Figure 1
Figure 2A~2B
Figure 2C~2D
AI summary
The invention relates to a process for modifying allergens to enhance their suitability in immunotherapy. The invention further relates to the modified allergens and pharmaceutical compositions thereof, as well as to their use in immunotherapy.